Lexicon Pharmaceuticals (LXRX) Stock Rockets On Positive Data

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) stock is making a run for the top in the market this morning, and for good reason. The company released positive Phase 3 data surrounding a diabetees treatment. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

LXRX Stock Rockets On Positive Data

In the press release, Lexicon Pharmaceuticals provided data from four Phase 3 clinical studies. The studies assessed sotagliflozin in patients with Type 2 diabetes. The company said that the final results of the studies will be preserved for upcoming medical congresses and publications.

Read more at Alpha Stock News!

Leave a Comment